MENU

Translational Medicine

Wafik S. El-Deiry, the deputy cancer center director for translational research and co-program leader in developmental therapeutics at Fox Chase, is an international leader in translational research and one of 40 active American Cancer Society Research professors.Wafik S. El-Deiry, the deputy cancer center director for translational research and co-program leader in developmental therapeutics at Fox Chase, is an international leader in translational research and one of 40 active American Cancer Society Research professors.

 

Vision

The vision of the translational medicine effort at Fox Chase is to discover and bring to patients new diagnostic and prognostic biomarkers, as well as devices and therapeutics, to positively impact the lives of people at risk of cancer as well as patients with cancer.

In order to increase the focus on translational science at Fox Chase Cancer Center, Wafik El-Deiry was recruited in 2014 as the deputy director for translational research and co-Leader of the molecular therapeutics research program.  Through the realization of his vision and through strategic planning, Fox Chase has increased its focus on translational research in order to more effectively bring basic research discoveries to clinical care.

Goals of translational research at Fox Chase Cancer Center

  • Fostering intra- and inter-programmatic collaborations
  • Prioritizing molecular targets and biomarkers
  • Assisting in the early development of translational research protocols
  • Increasing the number and support of investigator initiated translational clinical trials
  • Increasing the national presence for investigators and their translational research
  • Developing collaborations within the region
  • Increasing multi-investigator translational grant submissions

Features of translational research at Fox Chase

  • Translational Research Disease Groups
  • Annual retreat focused on translational medicine and precision medicine
  • Precision Medicine Steering Committee
  • Translational RFA Awards
  • Industry collaborations with Caris Life Sciences and others
  • Participation and leadership in the national MATCH clinical trial
  • Translational Research Support Resources